First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Arthritis Research and Therapy

Volumn 8, Issue 2, 2006, Pages

  Wittenberg, Ralf H ^a   Schell, Ernest ^b   Krehan, Gerhard ^c   Maeumbaed, Roland ^c   Runge, Hans ^c   Schlüter, Peter ^c   Fashola, Taiwo O A ^d   Thurston, Helen J ^d   Burger, Klaus J ^e   Trechsel, Ulrich ^d  

^a St Elisabeth Hospital Herten GmbH   (Germany)

^b Promedica GmbH   (Germany)

^c Novartis Pharma AG ^*  (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NOVARTIS PHARMA GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LUMIRACOXIB; ORGANIC COMPOUND; PYRAZOLE DERIVATIVE; SULFONAMIDE;

AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

AGED; ANALGESICS; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PYRAZOLES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247550758     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1854     Document Type: Article

References (41)

1. Schnitzer TJ: American College of Rheumatology. Update of ACR guidelines for osteoarthritis: Role of the coxibs. J Pain Symptom Manage 2002:S24-S30.
2. Dougados M: The role of anti-inflammatory drugs in the treatment of osteoarthritis: A European viewpoint. Clin Exp Rheumatol 2001:S9-S14.
3. American College of Rheumatology: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000, 43:1905-1915.
4. Vane J, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987, 1:89-96.
5. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
6. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999, 96 7563-7568.
7. Hernandez-Diaz S, Garcia Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: An overview of epidemiological studies published in the 1990s. Arch Intern Med 2000, 160 2093-2099.
8. Griffin MR, Yared A, Ray WA: Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000, 151:488-496.
9. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA: Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002, 41:458-461.
10. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999, 354:2106-2111.
11. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999, 117:776-783.
12. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, VIGOR Study Group, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
13. Buttgereit F, Burmester GR, Simon LS: Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med 2001:13S-19S.
14. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, et al.: Preclinical pharmacology of lumiracoxib: A novel selective inhibitor of cyclo-oxygenase- 2. Br J Pharmacol 2005, 144:538-550.
15. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C: Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects Drug Metab Dispos 2004, 32:566-571.
16. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G: Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects [abstract FRI0300] Ann Rheum Dis 2002:242.
17. Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U: Lumiracoxib demonstrates high absolute bioavailability in healthy subjects [abstract P-199]. Proceedings of the Sixth European Association of Clinical Pharmacology and Therapeutics (EACPT): 24-28 June 2003; Istanbul.
18. Scott G, Branson J, Milosavljev S, Rordorf C, Haraoui B, Ouellet JP, Schell E: Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee [abstract FRI0235]. Ann Rheum Dis 2003:267.
19. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, Weaver M, Huff JP, Ruff DA: Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004, 43:467-478.
20. Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SJ, Senftleber I, Gitton X, Moore A, Sloan VS, Poor G: Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 51:549-557.
21. Bijlsma JW: Analgesia and the patient with osteoarthritis. Am J Ther 2002, 9:189-197.
22. Celebrex® celecoxib capsules: Prescribing information [http://www.celebrex.com/information/Celebrex_PI.pdf]
23. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al.: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049.
24. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
25. Bauer P, Röhmel J, Maurer W, Hothorn L: Testing strategies in multi-dose experiments including active control. Stat Med 1998, 17:2133-2146.
26. Barden J, Edwards JE, McQuay HJ, Moore RA: Single dose oral celecoxib for postoperative pain. Cochrane Database Syst Rev 2003, 2 CD004233.
27. Moskowitz RW, Jones JB: Valdecoxib 10 mg demonstrates a rapid onset of action following a single dose in patients with OA of the knee in a flare state [abstract FRI0277]. Ann Rheum Dis 2003:279.
28. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial Mayo Clin Proc 1999, 74:1095-1105.
29. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS: Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001, 30:11-18.
30. Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, et al.: Lumiracoxib is effective in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis 2004, 63:1419-1426.
31. Fleischmann R, Sheldon E, Maldonado Cocco J, Yu S, Sloan VS: Lumiracoxib is effective in the treatment of osteoarthritis of the knee:a prospective randomized 13-week study versus placebo and celecoxib Clin Rheumatol 2006, 25:42-53.
32. Scott G, Rordorf C, Milosavljev S, Ferber G: Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis [abstract THU0233]. Ann Rheum Dis 2002:128.
33. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
34. Jensen MP, Chen C, Brugger AM: Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical trials of postoperative pain. J Pain 2003, 4:407-414.
35. Kellstein D, Ott D, Jayawardene S, Fricke J Jr: Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of postoperative dental pain. Int J Clin Pract 2004, 58:244-250.
36. Bitner M, Kattenhorn J, Hatfield C, Gao J, Kellstein D: Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea Int J Clin Pract 2004, 58:340-345.
37. Zelenakas K, Fricke J Jr, Jayawardene S, Kellstein D: Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004, 58 251-256.
38. ThompsoA WG: Placebos: a review of the placebo response. Am J Gastroenterol 2000, 95:1637-1643.
39. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, et al.: OsteoarthritiT: New insights. Part 1: the disease and its risk factors Ann Intern Med 2000, 133:635-646.
40. Falissard B, Ravaud P, Tubach F, Logeart I, Baron G, Dougados M: Determination of a minimal clinically meaningful difference in the WOMAC physical function score: Application of a new concept, the MDP75 [abstract FRI0236]. Ann Rheum Dis 2003:267.
41. Hawkey C, Hoexter G, Richard D, Gitton X, Weinstein W: Lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, has improved gastrointestinal safety and tolerability compared with nonselective nonsteroidal anti-inflammatory drugs: A pooled analysis [abstract 87] Arthritis Rheum 2003:79.